Please login to the form below
CRISPR
This page shows the latest CRISPR news and features for those working in and with pharma, biotech and healthcare.
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
TDT, and the rapid progress that we and our partners at CRISPR have made toward registration and commercialisation,” he added. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111
Latest news
-
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology. ... The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes.
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex is also looking to develop a CRISPR/Cas9 gene-editing therapy for the treatment of severe haemoglobinopathies in partnership with CRISPR therapeutics.
-
GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
The collaboration combines Vir Biotech’s monoclonal antibody platform technology with GSK’s expertise in functional genomics and capabilities in CRISPR screening to identify anti-coronavirus compounds.
-
Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
The initial areas of focus for the ATN are neurodegeneration, CRISPR-based therapeutics, protein degradation, functional genomics in human brain cells and sleep mechanisms and circuits. ... disorders; and developing therapeutics for brain diseases based
-
Takeda and KSQ Therapeutics to develop immune-based cancer treatments
Collaboration will utilise KSQ’s CRISPR-screening technology. Japanese pharma company Takeda has signed a collaboration agreement with KSQ Therapeutics to develop and market novel immune-based cancer therapies using its ... technology. KSQ’s
More from news
Approximately 16 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
With the introduction of new data analytics capabilities and broader adoption in the pharmaceutical industry, research platforms that heavily depend on data (eg, RNAi and CRISPR therapies) will likely increase their
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Horizon Delivery is also an industry leader in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screenings, meaning they can identify key genes or genetic sequences that draw out specific functions of
-
Switzerland: a life sciences hub
cells engineered to display chimeric antigen receptors) and genome editing (ie, CRISPR/Cas, TALEN, ZNF).
-
25 Women Leaders in UK Healthcare (part 2)
Pioneers in the field include some notable women – such as CRISPR’s co-developers Jennifer Doudna and Emmanuelle Charpentier – although women remain in the minority in both the R&D and
-
The trials and tribulations of rare opportunities
In turn, this has allowed the generation of models for a variety of rare diseases, particularly monogenic diseases where tools such as CRISPR/ Cas9 have enabled the creation of cell- and
More from intelligence
Approximately 2 fully matching, plus 17 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
Lundberg most recently served as chief scientific officer of CRISPR Therapeutics, where he lead the development of the company’s first clinical trial application. ... Prior to CRISPR, he worked as head of translational medicine at Alexion
-
Former GSK CEO joins Synthego’s advisory board
Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.
-
Marc Becker joins CRISPR Therapeutics
He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform. ... Becker said: “I am excited to join the CRISPR Therapeutics
-
CRISPR Therapeutics appoints Dr Tony Coles
Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors. ... Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track
More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full potential of cell &gene
-
Creative Animodel
Creative Animodel is an experienced bioscience CRO，which would like to help you accelerate the process through preclinical services including transgenic animals, animal models of disease, CRISPR genome editing technology and
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Live Webinar: Gamifying Surgical Training to Improve Patient Outcomes
- First trial of a vaccine against Alzheimer’s launches
- AZ appoints Susan Galbraith as executive vice president, oncology R&D
- Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
- MHRA approves second COVID-19 antibody treatment
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
